礼来减重口服药获得欧盟药品监管机构支持
礼来的减重口服药获得欧盟药品监管机构支持。Feed 未提供完整正文，未披露药品名称及监管决定的具体内容。
#减肥药
外媒与科技媒体长文、研究号文章。按时间排，不论是否入选精选。
路透社利好AI 评分6262
财富利好AI 评分2525 What a desert lizard teaches us about patents and the GLP-1 revolution
The GLP-1 story shows how patents can reward discovery and push rivals to develop better drugs.
MIT Technology ReviewAI 评分5050 MIT Technology Review梳理GLP-1减重药的副作用及儿童用药证据
MIT Technology Review梳理GLP-1减重药已报告的副作用及相关证据，包括常见的恶心、呕吐、腹泻和便秘，以及胰腺炎、胆结石、视力、脱发和指甲问题。文中指出，部分风险关联研究结果不一，指甲研究作者也未称药物导致指甲脱落；世卫组织在儿童肥胖指南中明确不建议对10岁以下儿童进行药物治疗，理由是相关获益及潜在不良事件证据不足。
MIT Technology ReviewAI 评分1515 The Download: weight-loss drugs slowing aging and carbon dioxide batteries
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. Weight-loss drugs show signs of slowing biological aging, say drugmakers Popular weight-loss drugs may do more than help people shed pounds. They might also slow
财富AI 评分3535 I’m an obesity expert and can’t wait for the compounding craze to stop
If you can't name the medical reason your patient needs a knockoff GLP-1, you don't have one.